TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06666946

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Description: Hwato brand disposable acupuncture needles (size 0.30 × 40 mm), and SDZ-V EA apparatuses will be used. Participants in the EA group will receive acupuncture at bilateral ST36 and GB34. After sterilisation, sterile adhesive pads will be placed on bilateral ST36 and GB34, and acupuncture needles will be inserted through the adhesive pads approximately 20 to 30 mm into the skin. Following needle insertion, manual manipulation of needles will be performed on all needles to reach de qi (a composite of sensations including soreness, numbness, distention, heaviness, and other sensations). Then, paired electrodes from the EA apparatus will be attached transversely to the needle handles at bilateral ST36 and GB34. EA stimulation lasted for 30 minutes with a continuous wave of 10 Hz and a current intensity of 0.5 to 1 mA (preferably with the skin around the acupoints shivering mildly without pain). Participants will receive 6 treatment sessions once daily for 6 consecutive days.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham electroacupuncture
Description: Non-insertive placebo needles (size 0.30 × 30 mm), and SDZ-V EA apparatuses will be used. Participants in the sham EA group will receive sham EA with a non-insertive placebo needle on sham acupoints. The sham ST36 point is located at 1 cun (≈20 mm) lateral to ST36, and the sham GB34 point is located at 1 cun (≈20mm) lateral to GB 34. Procedures, electrode placements, and other treatment settings will be the same as in the EA group but with no skin penetration, electricity output, or de qi.
Study: NCT06670170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016 Formulation A
Description: PF-07976016; formulation A - current/reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016 Formulation A
Description: PF-07976016; formulation A - current/reference

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016 Formulation B
Description: PF-07976016; Formulation B - new/test
Study: NCT04783519

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Behavioral Therapy for Insomnia (BBTI)
Description: Brief Behavioral Therapy for Insomnia (BBTI) focuses primarily on stimulus control and sleep restriction as well as sleep hygiene recommendations delivered over 2 in-person sessions and 2 brief telephone boosters and is designed to be implemented by nonspecialists in primary care or other non-clinical settings. The intervention is manualized, and clients utilize sleep diaries and workbook assignments to consolidate recommendations.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Brief Alcohol Screening and Intervention for College Students (BASICS)
Description: Brief Alcohol Screening and Intervention for College Students (BASICS) is a manualized brief intervention targeting alcohol use and consequences among high risk drinkers and includes both personalized feedback regarding drinking norms, consequences, and motives for drinking, as well as protective behavioral skills for reducing heavy episodic drinking and related consequences. BASICS is delivered in a motivational interviewing (MI) style (Miller \& Rollnick, 2002) to enhance intrinsic motivation to change drinking and implement protective behavioral strategies. BASICS has been adapted to target marijuana use and has been adapted for use with a variety of populations.
Study: NCT06670170

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-07976016 Formulation B
Description: PF-07976016; Formulation B - new/test
Study: NCT06666673

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tizanidine
Description: Tizanidine (TIZ) (Zanaflex®) is a centrally acting noradrenergic α-2 agonist and a ligand of I3 (non-I1/I2) imidazoline receptors. It is currently indicated for the management of spasticity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as control
Study: NCT06622161

Intervention type: DEVICE
Group type: OTHER
Intervention: automated oxygen vs manual oxygen
Description: Patient characteristics, ventilator, and blood gas parameters at the time of study will be shown in Tabular form. At the start of the study, half of the babies will be randomly assigned to a manual 12-hour period where a bedside nurse will adjust the FiO2 of the baby according to SpO2 levels, and half of the babies to an automated 12-hour period where Oxygenie will adjust FiO2 according to target SpO2 levels. After 12 hours, they will be shifted to contralateral intervention. The ventilator parameters (peak inspiratory pressure, positive end expiratory pressure, and rate) will be compared between the automated and manual 12-hour periods. The amount of time spent within different ranges of SpO2 will also be measured and shown in tabular form.

Intervention type: DEVICE
Group type: OTHER
Intervention: automated oxygen vs manual oxygen
Description: Patient characteristics, ventilator, and blood gas parameters at the time of study will be shown in Tabular form. At the start of the study, half of the babies will be randomly assigned to a manual 12-hour period where a bedside nurse will adjust the FiO2 of the baby according to SpO2 levels, and half of the babies to an automated 12-hour period where Oxygenie will adjust FiO2 according to target SpO2 levels. After 12 hours, they will be shifted to contralateral intervention. The ventilator parameters (peak inspiratory pressure, positive end expiratory pressure, and rate) will be compared between the automated and manual 12-hour periods. The amount of time spent within different ranges of SpO2 will also be measured and shown in tabular form.
Study: NCT06669884

Intervention type: OTHER
Intervention: Cardiodynamicsgram (CDG)
Description: Cardiodynamicsgram (CDG) technique
Study: NCT06370000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral Azacitidine
Description: Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.
Study: NCT04862390

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan

Intervention type: DEVICE
Intervention: Continuous glucose monitoring
Description: Home continuous glucose monitoring to be installed for two weeks during fasting Ramadan
Study: NCT05783297

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Treatment Text (TXTXT)
Description: This study will test a tailored, personalized SMS text message reminder intervention to improve adherence to ART among non-adherent youth and young adults with HIV. Participants will use their own cell phones for receipt of the intervention. Participants will have the option to choose a tailored personalized message that may be changed as requested throughout the 6-month intervention period. Participants will be asked to send a text message response indicating that that have successfully (or not) taken their meds per schedule. No identifying patient information will be included in the SMS text to protect patient confidentiality.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Standard of care ART adherence support includes adherence counseling during visits scheduled at least twice annually and appointment reminders.
Study: NCT06161402

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Elastic band-based progressive resistance training (EB-PRT)
Description: EB-PRT will be implemented during week 1-14. The EB-PRT comprises a 4-week training phase, 6-week consolidation phase and a 4-week maintenance phase.
Study: NCT06179485

Intervention type: DRUG
Intervention: Ketamine
Description: The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the ketamine group will be assigned to receive intravenous ketamine for induction of anesthesia during tracheal intubation. A dose of 2 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of ketamine than recommended if felt to be required for optimal patient care.

Intervention type: DRUG
Intervention: Etomidate
Description: The RSI-LTO study collects long-term outcomes from the RSI trial (NCT05277896). In the RSI trial, patients in the etomidate group will be assigned to receive intravenous etomidate for induction of anesthesia during tracheal intubation. A dose of 0.3 mg/kg will be recommended, and the group assignment sheet will contain a nomogram providing the recommended dose for a range of patient weights (in pounds and kg). Treating clinicians will be able elect to give a lesser or greater dose of etomidate than recommended if felt to be required for optimal patient care.
Study: NCT06402201

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CDR404
Description: IV infusions
Study: NCT06647225

Intervention type: DEVICE
Group type: OTHER
Intervention: Artificial intelligence augmented ultrasound
Description: The hip ultrasound is performed using a handheld device (Exo Iris) that uses a pocket-sized ultrasound probe and is run through an application on an IoS (Apple mobile) operation system. . A real-time algorithm detects and records the anatomical landmarks. When there are enough images for analysis the operator is notified that the scan is complete. From here, the images are then classified as: the hips as healthy, follow-up recommended, or suboptimal (repeat scan).
Study: NCT05770284

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12 weeks exercise
Description: 12 weeks exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Treatment
Description: Standard Medical Treatment
Study: NCT05063929

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fruit (2 cup eq)
Description: participants will receive 2 cup eq fruits

Intervention type: OTHER
Group type: OTHER
Intervention: Fruit restriction (1/2 cup eq)
Description: participants will receive 1/2 cups eq fruits
Study: NCT06546202

Intervention type: OTHER
Intervention: No Drug
Description: This is an non-interventional, observational study. No drug was administered during this study.

Intervention type: OTHER
Intervention: No Drug
Description: This is an non-interventional, observational study. No drug was administered during this study.
Study: NCT06189807

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Decision aid
Description: Enrolled participants will be sent the novel educational decision aid about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment, study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard handout
Description: Enrolled participants will be sent the standard information about pregnancy, birth control, and kidney disease and asked to read that information prior to a standard of care appointment with participants nephrologist. Prior to the appointment study staff will provide participants with a paper version of the materials that had previously been sent. During the appointment, the participant's nephrologist may review the materials with the participant and answer any questions. Following the appointment, participants will be asked to complete a short survey about: the experience using the materials, experience about being counseled about pregnancy and birth control during visit, willingness to use such materials in the future, and information about participants kidney disease diagnosis.
Study: NCT06685354

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: hepatic arterial infusion of recombinant human type 5 adenovirus
Description: Participants will receive hepatic arterial infusion of recombinant human type 5 adenovirus (H101). The H101 treatment regimen consists of 3 cycles or until a specific treatment discontinuation event occurs as outlined in the protocol. The H101 administration method is as follows: if the sum of the largest diameters of lesions is ≤10 cm, the total dose is 1.0×10\^12 vp (2 vials); if the sum of the largest diameters is \&gt;10 cm, the total dose is 1.5×10\^12 vp (3 vials). Treatment cycles are every 3 weeks.
Study: NCT06683443

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Robotic Joy for All™ pet
Description: Patients will be provided with the robotic pet within 48 hours of admission and have access to the pets throughout their hospitalization to provide comfort and engagement.
Study: NCT06685484

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Mindfulness Training Program (MMTP)
Description: The intervention, designed as a Modified Mindfulness Training Program (MMTP), aims to reduce antenatal depression and perceived stress among pregnant women, especially those with a preference for a male child. This program is adapted to address culturally specific stressors relevant to these women, promoting mental health and resilience during pregnancy.~The intervention is based on Nola Pender's Health Promotion Model and structured using the ADAPT-ITT framework, which includes Assessment, Decision, Adaptation, Production, Topical Experts, Integration, Training, and Testing phases. This phased approach ensures cultural relevance and feasibility within the target population of pregnant women in Pakistan.~Duration and Frequency: The intervention consists of six weekly sessions, each lasting two hours, held in a serene, controlled environment within a seminar room at Sindh Govt. Qatar Hospital, Karachi.
Study: NCT06006585

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 771716
Description: BI 771716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 771716
Description: BI 771716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 771716
Description: BI 771716

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 771716
Description: BI 771716
Study: NCT05479578

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Given PO
Study: NCT05611749

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine 60 MG
Description: Looking at the use of duloxetine's effect with regards to perioperative narcotics consumption and patient outcomes after lumbar fusion.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Duloxetine versus placebo in reducing postoperative narcotic consumption among patients undergoing lateral lumbar interbody fusions
Study: NCT05503849

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Description: This lifestyle modification aiming to provide proactive health management during pregnancy, which contains the following: 1) balanced dietary intake based on the Chinese Dietary Guideline; 2) sufficient physical activity; 3) changes in lifestyles (e.g. sleep, sun exposure etc.)
Study: NCT06194331

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: iCHART/cASAP
Description: When patients disclose suicidal ideation on the PHQ-9, the intervention of iCHART/cASAP will be implemented in the pediatrician's office, and in collaboration with parents, which includes safety planning, teaching skills to improve distress tolerance and emotion regulation all on the teen's smart device. iCHART/cASAP will include: Screening Wizard, a digital screening tool that will guide the provider to gauge patient satisfaction with current treatment and making further personalized treatment recommendations; cASAP, a computerized version of the As Safe As Possible intervention that focuses on psychoeducation in safety planning, distress tolerance, and emotion regulation skills; BRITE, a safety planning app with distress monitoring that a teen can be guided through with automated onboarding manuals; Text2Connect, an automated text messaging sent centrally to patients and parents to enhance treatment adherence.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual
Description: When patients disclose suicidal ideation on the PHQ-9, a treatment as usual approach will be given to the patient and their parent by the pediatrician which includes a paper safety plan will be completed and given to the patient and a referral placed for the patient to begin behavioral health services.
Study: NCT05572047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Arga Medtech Coherent Sine-Burst Electroporation (CSE) Ablation System
Description: Use of coherent sine-burst electroporation to ablate paroxysmal and persistent AF
Study: NCT04941950

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PlaySmart
Description: PlaySmart is designed to provide players with behavioral skills and knowledge through repetitive and engaging videogame play to target adolescent perception of risk of harm from initiating opioid misuse.

Intervention type: OTHER
Group type: OTHER
Intervention: Video Game Control
Description: Participants in the control group will play another video game with no intended effect similar to PlaySmart.
Study: NCT05557565

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: The dosage of QL1706 is 5.0 mg/kg, and QL1706 is administered every 3 weeks (Q3W) by intravenous infusion
Study: NCT04659915

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin 500 mg Oral Tablets + Prednisone 20mg Tablets
Description: During one phase of the study: Metformin 500mg Day 1 1-0-0 Day 2 1-0-0 Day 3 1-0-1 Day 4 1-0-1 Day 5 2-0-1 Day 6 2-0-1 Day 7 4-0-0~In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 500 mg Tablets + Prednisone 20mg Tablets
Description: During another phase of the study: identical looking placebo pills starting day 1 500mg 1-0-0, day 2 500mg 1-0-0, day 3 500mg 1-0-1, day 4 500mg 1-0-1, day 5 500mg 2-0-1. day 6 2-0-1, day 7 4-0-0. In combination with prednisone 20mg: day 1 to day 7 1.5-0-0.
Study: NCT06057454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: R-5280
Description: Modified Superior Starch

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Food Grade Starch
Study: NCT05511922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KVD900 600 mg
Description: KVD900 Tablet 600 mg (2 x 300 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug: KVD900 300 mg
Description: KVD900 Tablet 300 mg
Study: NCT05470036

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Educational intervention.
Description: Educational intervention with trained educator on overview, rationale, implications, and risks and benefits of germline testing in prostate cancer.
Study: NCT04872543

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASTX727
Description: ASTX727 will be self-administered orally by the patient on a once daily basis, days 1 through 5 of each 21-day cycle. Cycle 1 day 1 (C1D1) is defined as the first day that ASTX727 is administered.
Study: NCT05493072

Intervention type: OTHER
Group type: OTHER
Intervention: RxConnect
Description: Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: RxConnect
Description: Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: RxConnect
Description: Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.

Intervention type: OTHER
Group type: OTHER
Intervention: RxConnect
Description: Participants use RxConnect, an on-demand clinical decision support tool that receives medication and patient inputs and uses them to filter an underlying formulary, such as the BNF, and perform dosing calculations, as needed, to return patient-specific dosing recommendations.
Study: NCT06684002

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates training
Description: The program consisted of Pilates exercises on the reformer for 40 minutes.